Antigen binding proteins capable of binding thymic stromal lymphopoietin
AssigneeAmgen Inc.
InventorsMichael R Comeau, James F Smothers, Bo-Rin P Yoon, Christopher Mehlin
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.
Claims7
An isolated antibody or antigen binding fragment thereof comprising
- a. a light chain variable domain comprising:
- i. a light chain CDR1 sequence comprising the amino acid sequence of SEQ ID NO:13;
- ii. a light chain CDR2 sequence comprising the amino acid sequence of SEQ ID NO:60;
- and
- iii. a light chain CDR3 sequence comprising the amino acid sequence of SEQ ID NO:105;
- and
- b. a heavy chain variable domain comprising:
- i. a heavy chain CDR1 sequence comprising the amino acid sequence of SEQ ID NO:145;
- ii. a heavy chain CDR2 sequence comprising the amino acid sequence of SEQ ID NO:173, and
- iii. a heavy chain CDR3 sequence comprising the amino acid sequence of SEQ ID NO:212;
- wherein the antibody or antigen binding fragment thereof binds a wild-type TSLP polypeptide consisting of amino acids 29-159 as set forth in SEQ ID NO:
- 2 with a greater affinity than the antibody or antigen binding fragment thereof binds to a mutated TSLP polypeptide consisting of amino acids 29-159 as set forth in SEQ ID NO:
- 2 but comprising a serine to arginine mutation at position 40 (S40R).
Dependencies are inferred from the claim text.